Quince Therapeutics: Of The Original Report To Include The Audited Financial Statements Of Orphai As Of And For The Years Ended December31, 2025 And 2024 And The Unaudited Interim Condensed Consolidated Financial Statements Of Orphai As Of And For The Three Months Ended March31, 2026 And 2025; And (ii)update The Information In Item 9.01(b) Of The Original Report To Include The Unaudited Pro Forma Condensed Consolidated Financial Information Of The Company As Of And For The Three Months Ended March31, 2026 And The Year Ended December31, 2025. The Financial Statements Have Been Presented For Orphai, Which Was The Entity That Held All Of The Assets Acquired. None Of The Assets Acquired Were Attributable To Holdco. Additionally, This Amendment No.2 Is Filed To Incorporate By Reference Business And Risk Factor Information Of Orphai. This Amendment No.2 Does Not Amend Any Other Item Of The Original Report, Other Events

Show full article

This functionality is available for registred users only

• Full name
  Quince Therapeutics Inc
• Registration country
  USA
• Industry
  Pharmaceutical Preparation and Biotechnology
• М/S&P/F
  *** / *** / ***